Inicio/Acciones/PCRX

PCRX

USD

Pacira BioSciences Inc. Common Stock

$24.450+0.100 (0.411%)

Precio en Tiempo Real

Healthcare

Drug Manufacturers - Specialty & Generic

Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado

Fundamentos de la Empresa

Estadísticas de Negociación

Métricas de Mercado

Apertura

$24.350

Máximo

$24.590

Mínimo

$23.500

Volumen

0.18M

Fundamentos de la Empresa

Capitalización de Mercado

1.1B

Industria

Drug Manufacturers - Specialty & Generic

País

United States

Estadísticas de Negociación

Volumen Promedio

0.89M

Bolsa

NMS

Moneda

USD

Rango de 52 Semanas

Mínimo $11.16Actual $24.450Máximo $29.61

Noticias Relacionadas

27 may 2025 · 01:54

GlobeNewswire

Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO Securities Technologies, Inc. (NASDAQ: NSSC); Pacira Biosciences, Inc. (NASDAQ: PCRX); and Treace Medical Concepts, Inc. (NASDAQ: TMCI)

PHILADELPHIA, May 26, 2025 (GLOBE NEWSWIRE) -- DoubleVerify Holdings, Inc. (NYSE:DV): If you have held DoubleVerify Holdings, Inc. (NYSE:DV) shares since prior to November 10, 2023, and would like to learn

Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO Securities Technologies, Inc. (NASDAQ: NSSC); Pacira Biosciences, Inc. (NASDAQ: PCRX); and Treace Medical Concepts, Inc. (NASDAQ: TMCI)

15 may 2025 · 12:00

GlobeNewswire

Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee

-- Early clinical data indicates that Pre-existing and treatment-induced anti-Ad5 neutralizing antibodies do not impact the safety and effectiveness of PCRX-201 – -- An oral presentation of the data to be featured at